Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast - 2025

Publisher Name :
Date: 28-Jul-2017
No. of pages: 70
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Malignant Mesothelioma for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Malignant Mesothelioma . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Malignant Mesothelioma for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Malignant Mesothelioma market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Malignant Mesothelioma , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Malignant Mesothelioma for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Malignant Mesothelioma 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Malignant Mesothelioma market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

  • Understanding historical and forecasted epidemiological data for Malignant Mesothelioma covering 7MM from 2015-2025.

  • Segment level epidemiology and market split for Malignant Mesothelioma .

  • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Malignant Mesothelioma .

  • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Malignant Mesothelioma market trends.

  • Thorough market distribution based on market share for Malignant Mesothelioma .

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.

  • To understand the future market competition in the Malignant Mesothelioma market and Insightful review of the key market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for Malignant Mesothelioma in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast - 2025

Table of Contents

1. Report Introduction

2. Malignant Mesothelioma Market Overview at a Glance
2.1. Total Market Share Distribution of Malignant Mesothelioma for 7 MM in 2016
2.2. Total Market Share Distribution of Malignant Mesothelioma for 7 MM in 2025

3. Malignant Mesothelioma
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment

4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Malignant Mesothelioma in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Malignant Mesothelioma in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Malignant Mesothelioma in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Malignant Mesothelioma in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Malignant Mesothelioma in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Malignant Mesothelioma in United Kingdom

5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices

6. Marketed Drugs for Malignant Mesothelioma
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status

7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase

8. Overview of Total Malignant Mesothelioma Market (2016 & 2025)

9. Malignant Mesothelioma : Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)

10. Market Drivers

11. Market Restraints

12. Appendix

13. Report Methodology

14. Consulting Services

15. Disclaimer

16. About DelveInsight

List of Tables

Table 1: Diagnosed Cases Malignant Mesothelioma in United States (2015-2025)
Table 2: Diagnosed Cases Malignant Mesothelioma in Germany (2015-2025)
Table 3: Diagnosed Cases Malignant Mesothelioma in France (2015-2025)
Table 4: Diagnosed Cases Malignant Mesothelioma in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Malignant Mesothelioma in Spain (2015-2025)
Table 6: Diagnosed Cases Malignant Mesothelioma in Italy (2015-2025)
Table 7: Diagnosed Cases Malignant Mesothelioma in Japan (2015-2025)
Table 8: List of Marketed Drugs for Malignant Mesothelioma
Table 9: List of Pipeline Phase III Drugs for Malignant Mesothelioma
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Table 17: Germany Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Table 18: France Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Table 20: Spain Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Table 21: Italy Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Table 22: Japan Market Size of Malignant Mesothelioma in USD, Million (2015-2025)

List of Figures

Figure 1: Diagnosed Cases Malignant Mesothelioma in United States (2015-2025)
Figure 2: Diagnosed Cases Malignant Mesothelioma in Germany (2015-2025)
Figure 3: Diagnosed Cases Malignant Mesothelioma in France (2015-2025)
Figure 4: Diagnosed Cases Malignant Mesothelioma in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Malignant Mesothelioma in Spain (2015-2025)
Figure 6: Diagnosed Cases Malignant Mesothelioma in Italy (2015-2025)
Figure 7: Diagnosed Cases Malignant Mesothelioma in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Malignant Mesothelioma
Figure 9: List of Pipeline Phase III Drugs for Malignant Mesothelioma
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Figure 17: Germany Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Figure 18: France Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Figure 20: Spain Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Figure 21: Italy Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
Figure 22: Japan Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
  • Global Cancer Immunotherapy Market Analysis & Forecast to 2022 Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors
    Published: 23-Oct-2017        Price: US 4900 Onwards        Pages: 370
    Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance. This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022. This report describes the evolution of such a huge market in 20 chapte......
  • Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 254
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-......
  • Peritoneal Cancer - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 876
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H2 2017, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal......
  • Rhabdomyosarcoma - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 226
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2017, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness.......
  • Fallopian Tube Cancer - Pipeline Review, H2 2017
    Published: 10-Oct-2017        Price: US 2000 Onwards        Pages: 875
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2017, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopaus......
  • Global Kaposi Sarcoma Market Size, Status and Forecast 2022
    Published: 06-Oct-2017        Price: US 3300 Onwards        Pages: 98
    This report studies the global Kaposi Sarcoma market, analyzes and researches the Kaposi Sarcoma development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Merck - Pfizer - Johnson & Johnson - GlaxoSmithKline - Bristol-Myers Squibb - Eli Lilly Market segment by Regions/Countries, this report covers - United States - EU - ......
  • Oligodendroglioma - Pipeline Review, H2 2017
    Published: 30-Sep-2017        Price: US 2000 Onwards        Pages: 148
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H2 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor......
  • Esophageal Cancer - Pipeline Review, H2 2017
    Published: 30-Sep-2017        Price: US 2000 Onwards        Pages: 591
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H2 2017, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.......
  • Global Cancer Supportive Care Market 2017-2021
    Published: 21-Sep-2017        Price: US 3500 Onwards        Pages: 96
    Cancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cancer pain, and others. Various class of drugs are used as cancer supportive care drugs. Some of the major drug class that involves in cancer supportive care are antiemetic drugs, erythropoietin-stimulating agents, granulocyte-stimulating agents, analgesics, and others. The analysts forecast global cancer supportive ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs